<dpo class="mocynh"></dpo>

南宫NG28基因

Be the most trusted biotech company

2026-01-09

ASCO GI 2026 | Henlius Accelerates Global Phase 3 Head-to-Head Development of HLX22 as First-Line Treatment for HER2-Positive Gastric Cancer
2026-01-09

Henlius Debuts Phase 2 Results for Its Broad Anti-tumor PD-L1 ADC HLX43 in Second-Line or Subsequent Treatment of Esophageal Squamous Cell Carcinoma at ASCO GI 2026
2026-01-07

Live Webcast | Henlius to Present at JPM 2026, Outlining Its Globalization 2.0 Pathway

1
...
5
6
7
8